Deals In Depth: March 2014
Executive Summary
In a deal worth $139 million, UCB and Sanofi are pursuing anti-inflammatory medications for GI conditions and arthritis; Sterigenics bought isotope maker Nordion for $727 million. Public offerings again drove biopharma financing, making up more than 50% of the $3.4 billion raised; device financing totaled $219 million, with most of the funding from debt and FOPO transactions.
You may also be interested in...
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
Medtronic Adds Smart Insulin Pen By Acquiring Companion Medical
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.
Need a specific report? 1000+ reports available
Buy Reports